Clinical Trials
5 trialsNCT01681433 2022-07-11
OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone
Hoosier Cancer Research Network
Phase 2 Terminated
NCT01780545 2022-07-11
Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT01120470 2019-02-15
OGX-427 in Castration Resistant Prostate Cancer Patients
British Columbia Cancer Agency
Phase 2 Completed
NCT01454089 2016-10-07
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
Achieve Life Sciences
Phase 2 Completed
NCT00959868 2012-02-13
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
Vancouver Coastal Health
Phase 1 Unknown